[Translation]

October 23, 2026

MEDIPAL HOLDINGS CORPORATION
Representative: Kuniaki Imagawa, Representative Director, President and CEO
Code number: 7459 (Prime Market, Tokyo Stock Exchange)
Contact: Toshiyuki Ikeuchi,
Executive Officer, Head of Corporate Communications Department,
Corporate Planning Division
Tel: +81-3-3517-5171

Notice Regarding Revision of Full-Year Consolidated Financial Forecasts

MEDIPAL HOLDINGS CORPORATION (the "Company") hereby announces that it has revised its full-year consolidated financial forecasts for the fiscal year ending March 31, 2027 (April 1, 2026 to March 31, 2027), which were previously announced on July 14, 2026, as follows.

1. Revision of Full-Year Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2027 (April 1, 2026 to March 31, 2027)

	Net Sales	Operating Profit	Ordinary Profit	Profit Attributable to Owners of Parent	Earnings per Share
	(¥ million)	(¥ million)	(¥ million)	(¥ million)	(¥)
Previous Forecast (A)	3,944,000	53,500	67,500	43,000	210.06
Revised Forecast (B)	3,944,000	53,500	67,500	53,000	258.92
Change (B -A)	–	–	–	10,000	48.86
Change (%)	–	–	–	23.3%	
(Reference) Previous Results (FY ended March 31, 2026)	3,817,354	53,182	75,723	42,534	206.67

(Reasons for Revision)

As described in the "Notice Regarding Recording of Gain on Sale of Investment Securities (Extraordinary Income)" announced today, as a result of recording gains on the sale of investment securities (extraordinary income) in connection with the reduction of strategic shareholdings, etc., profit attributable to owners of the parent in the full-year consolidated financial results for the fiscal year ending March 31, 2027, is expected to exceed the previous forecast.

(Note) The consolidated financial forecasts are based on information currently available to the Company as of the date of publication of this document, and the Company does not promise or guarantee achievement of these forecasts. Actual consolidated financial results may differ from the forecasts due to various factors in the future.

# # #

The English version of this document is a translation of the Japanese original and is provided for informational purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. If there are any inconsistencies or conflicts between the English version and the Japanese original, the Japanese original shall prevail.